Immuno-Cell Int. Company Profile

08:53 EDT 19th March 2018 | BioPortfolio

Immuno-Cell International © is specialized in the production of printed diagnostic slides and plates, for use in various types of diagnostic test kits. For the Diagnostic Industry (the manufactures of diagnostic test kits) we mostly manufacture these slides and cards custom-made (O.E.M. product). In addition we offer a wide range of standard items, which are available with low minimum order requirements. We supply our slides and cards to the leading test kits manufacturers. The secret of our success is due not only to our high quality product and the service that we povide, but also to the fact that we offer the most complete range of products in the field of diagnostic slides and cards


Hanswijk Ind.Park Motstraat 72/8


Phone: 32-15-43.31.88
Fax: 32-15-43.11.21

News Articles [1479 Associated News Articles listed on BioPortfolio]

NANOBIOTIX: NANOBIOTIX: FDA approves Nanobiotix's first Immuno-Oncology trial


Catalent, Grid Therapeutics in Immuno-Oncology Alliance

Will leverage GPEx cell line technology to develop cell lines and manufacture antibodies for optimization

AbbVie and Harpoon Therapeutics Enter Immuno-Oncology Research Collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company devel...

FDA Approves Nanobiotix's First Immuno-Oncology Trial: a Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody

First Nanobiotix immuno-oncology trial will be conducted in the U.S. Multi-arm trial targets sub-population of advanced and metastatic lung (NSCLC), and head and neck cancer patients (HNSCC). Eval...

Crown Bioscience enhances CAR-T cell therapy with bioluminescent imaging

CrownBio, a specialist in the field of preclinical immuno-oncology research, offers a chimeric antigen receptor T-cell platform for proof-of-concept and therapeutic efficacy validation

Horizon licenses ‘copy and paste’ tech to optimise commercial cell line

Horizonâs gene editing technology will be used by a US immuno-oncology firm to make a cell line for commercial use.

Horizon Discovery enters agreement with immuno-oncology company

Horizon Discovery Group, specialists in gene editing and gene modulation technologies, has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer f...

Five Prime Therapeutics Triggers $5M Milestone

The first clinical candidate from the collaboration is a fully-human monoclonal antibody targeting TIM-3 , an immune checkpoint receptor that is known to limit the duration and magnitude of T-cell res...

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Sun care [Zenith Medicosm SL]

Drug Facts

Sun care [Zenith Medicosm SL]

Drug Facts

Alimta [Eli Lilly and Company]

These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA. ALIMTA (pemetrexed for injection) Lyophilized Powder, for ...

Hycamtin [GlaxoSmithKline LLC]

These highlights do not include all the information needed to use HYCAMTIN safely and effectively. See full prescribing information for HYCAMTIN. HYCAMTIN (topotecan) CapsulesInitial U.S. Approval: 19...

Patanol [Physicians Total Care, Inc.]

PubMed Articles [2763 Associated PubMed Articles listed on BioPortfolio]

Development and Comparison of Two Immuno-disaggregation Based Bioassays for Cell Secretome Analysis.

Cell secretome analysis has gained increasing attention towards the development of effective strategies for disease treatment. Analysis of cell secretome enables the platform to monitor the status of ...

Disseminated histoplasmosis in an immuno-competent young male: Role of bone marrow examination in rapid diagnosis.

Fungal infections are usually seen in elderly or immuno-compromised individuals particularly with human immunodeficiency virus infection. In immuno-competent individuals, they seldom present with over...

Inhibin-A and inhibin-B in cyclic and pregnant mares, and mares with granulosa-theca cell tumors: Physiological and diagnostic implications.

Studies in mares have examined serum inhibin concentrations using immuno-assays unable to distinguish dimeric inhibin-A from inhibin-B isoforms. Inhibin-A and inhibin-B immuno-assays were used to inve...

Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.

Galectins (S-type lectins) are an evolutionarily-conserved family of lectin molecules, which can be expressed intracellularly and in the extracellular matrix, as well. Galectins bind β-galactose-cont...

A Case for a Human Immuno-Peptidome Project Consortium.

A multidisciplinary group of researchers gathered at the Hönggerberg Campus at ETH Zurich, Switzerland, for the first meeting on the Human Immuno-Peptidome Project (

Clinical Trials [6387 Associated Clinical Trials listed on BioPortfolio]

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cel...

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patient...

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer ...

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Autologous Tcm cells immunotherapy combining surgery or chemotherapy could effectively prolong survival period and improve quality of life in patients.

Companies [1004 Associated Companies listed on BioPortfolio]

Immuno-Cell Int.

Immuno-Cell International © is specialized in the production of printed diagnostic slides and plates, for use in various types of diagnostic test kits. For the Diagnostic Industry (the manufactures o...


Manufacture of slides and cards for use in test kits.

NantCell, Inc.

NantCell, an entity controlled by Dr. Patrick Soon-Shiong, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by de...

Immuno Diagnostic Oy

Immuno Diagnostic Oy was established in 1983. Thus, we have a long experience in importing and marketing high quality reagents for diagnostics and research. We provide our customers with a wide range ...

MEDINET Co., Ltd. and MaxCyte, Inc.

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technol...

More Information about "Immuno-Cell Int." on BioPortfolio

We have published hundreds of Immuno-Cell Int. news stories on BioPortfolio along with dozens of Immuno-Cell Int. Clinical Trials and PubMed Articles about Immuno-Cell Int. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immuno-Cell Int. Companies in our database. You can also find out about relevant Immuno-Cell Int. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record